Source:http://linkedlifedata.com/resource/pubmed/id/19705064
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-10-15
|
| pubmed:abstractText |
Targeting cellular mitosis is an attractive antitumor strategy. Here, we reported MT7, a novel compound from the 6H-Pyrido[2',1':2,3]imidazo [4,5-c]isoquinolin- 5(6H)-one library generated by using the multi-component reaction strategy, as a new mitotic inhibitor. MT7 elicited apparent inhibition of cell proliferation by arresting mitosis specifically and reversibly in various tumor cell lines originating from different human tissues. Detailed mechanistic studies revealed that MT7 induced typical gene expression profiles related to mitotic arrest shown by cDNA microarray assays. Connectivity Map was used to analyze the microarray data and suggested that MT7 was possibly a tubulin inhibitor due to its similar gene expression profiles to those of the known tubulin inhibitors demecolcine, celastrol and paclitaxel. Further analyses demonstrated that MT7 inhibited the polymerization of cellular microtubules although it was not detectable to bind to purified tubulin. The inhibition of cellular tubulin polymerization by MT7 subsequently resulted in the disruption of mitotic spindle formation, activated the spindle assembly checkpoint and consequently arrested the cells at mitosis. The persistent mitotic arrest by the treatment with MT7 led the tested tumor cells to apoptosis. Our data indicate that MT7 could act as a promising lead for further optimization, in hopes of developing new anticancer therapeutics and being used to probe the biology of mitosis, specifically, the mode of interference with microtubules.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1573-0646
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
715-28
|
| pubmed:meshHeading |
pubmed-meshheading:19705064-Antimitotic Agents,
pubmed-meshheading:19705064-Apoptosis,
pubmed-meshheading:19705064-Cell Line, Tumor,
pubmed-meshheading:19705064-Cell Proliferation,
pubmed-meshheading:19705064-Combinatorial Chemistry Techniques,
pubmed-meshheading:19705064-Drug Screening Assays, Antitumor,
pubmed-meshheading:19705064-Gene Expression Profiling,
pubmed-meshheading:19705064-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19705064-Genes, Neoplasm,
pubmed-meshheading:19705064-Heterocyclic Compounds with 4 or More Rings,
pubmed-meshheading:19705064-Humans,
pubmed-meshheading:19705064-Microtubules,
pubmed-meshheading:19705064-Mitosis,
pubmed-meshheading:19705064-Mitotic Spindle Apparatus,
pubmed-meshheading:19705064-Small Molecule Libraries,
pubmed-meshheading:19705064-Tubulin,
pubmed-meshheading:19705064-Up-Regulation
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules.
|
| pubmed:affiliation |
Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, People's Republic of China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|